Truly human antibody therapeutics.
Humans mount lasting antibody responses to infectious diseases and cancer. Abterra Bio uses next-generation sequencing, mass spectrometry, and machine learning to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.
Abterra Bio technology is built on decades of experience in antibody sequencing and analysis. Click on the services below to see how we can help you!
REPTOR™
Next-Gen Sequencing Hybridoma
REPTOR™
Next-Gen Sequencing Bulk B Cells
REPTOR™
Next-Gen Sequencing Hit Expansion
REPTOR™
Next-Gen Sequencing Display Library
ALICANTO®
Rabbit Monoclonal Antibody Discovery
ALICANTO®
Single Domain (VHH) Antibody Discovery
ALICANTO®
Human Antibody Discovery
VALENS™
Protein Sequence Confirmation
VALENS™
Antibody Protein Sequencing
Our partners’ success means everything to us
I have had great experiences using Abterra Bio’s Reptor platform. The data generated was highly valuable, and the team provided quick and open communication throughout the whole process.
Latest News
Problem Solvers by Nature
"When @necastellana began applying algorithms for protein analysis, she realized that most methods did not utilize the power of the human body’s adaptive immune system." Read about how to unlock the power of the human immune system using bioinformatics.
Alicanto Innovative New Product Award Finalist
We’re thrilled to announce that Alicanto® was selected as a finalist in CONNECT’s Most Innovative New Product Awards. CONNECT, a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences sectors,...
Phase 1 SBIR Award-Quorum Cloud
Quorum Cloud® is a computational platform that organizes tandem MS data into molecular networks. Molecular networks connect related compounds that differ by a mutation, modification, or adduct. Quorum Cloud® increases NP compound annotations compared to previous...
Scientific Updates
Clonal Hit-Expansion Case Study
Abterra Bio uses next-generation sequencing to mine the clonal lineage of serum-identified antibodies. This method rescues relatives of hits that are within a clone and increases diversity in your antibody discovery campaign. Contact us to learn more about how our...
Llama Immune Repertoire Profiling
Alicanto® is Abterra Biosciences' proprietary antibody discovery platform that mines the entire immune response to identify diverse, functional antibodies. For an overview of the proteogenomic process, read more about Alicanto®. The infographic below was created using...
Alicanto Antibody Discovery – Diversity
Alicanto® is Abterra Biosciences' proprietary antibody discovery platform that mines the entire immune response to identify diverse, functional antibodies. For an overview of the proteogenomic process, read more about Alicanto®. Alicanto benefits include: Full...
Antibody Reference Guide
We developed a one-sheet antibody reference that is handy for antibody-related work. We refer to it often to remind ourselves of the major antibody isotypes, antibody fragments, and purification strategies, as well as antibody development processes. Below we outline...
Every day, we strive to help our partners and collaborators push the boundaries of their science.
